Expand your knowledge.
Listen to Key Opinion Leader Dr. Naim Alkhouri discuss the latest data regarding alternative therapies for NASH patients with metabolic disorders. Topics include:
Naim Alkhouri, MD
Chief Medical Officer,
Chief of Transplant Hepatology,
Director of the Fatty Liver Program
Arizona Liver Health
Naim Alkhouri, M.D., is the Chief Medical Officer (CMO), Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ. Prior to joining ALH, Dr. Alkhouri served as the director of the Metabolic Health Center at the Texas Liver Institute and Associate Professor of Medicine and Pediatrics at the University of Texas (UT) Health in San Antonio, TX.
Dr. Alkhouri completed his Gastroenterology and Transplant Hepatology training at the renowned Cleveland Clinic, where he was also appointed Assistant Professor of Medicine and Director of the Metabolic Liver Disease Clinic at the Cleveland Clinic Digestive Disease and Surgery Institute.
An author of over 200 publications, Dr. Alkhouri is considered a key opinion leader in the field of NASH therapeutics and serves as a member of the AASLD NASH Special Interest Group (NASH SIG). He acts as an advisor to many pharmaceutical and biomarker development companies and is Principal Investigator on several multicenter global NASH trials.
Dr. Alkhouri is the recipient of a number of research awards, including the American College of Gastroenterology Junior Faculty Development Award.
Julia PinterMarketing Director
Julia Pinter brings over a decade of medical technology marketing experience spanning product commercialization, launch strategy, and sales enablement. Prior to joining Sonic Incytes, she served as Director of Global GI Product Marketing at PENTAX Medical, where she led global downstream marketing for the company’s largest portfolio — driving commercial launches of next-generation endoscopes, imaging systems, and AI platforms across the Americas, Europe, and Asia-Pacific. At Sonic Incytes, Julia leads downstream marketing initiatives to expand awareness and accelerate adoption of Velacur One®, translating its clinical and economic value into programs that support broader adoption of non-invasive liver assessment.